NEW YORK (GenomeWeb) – Myriad Genetics reported in an 8-K filing with the US Securities and Exchange Commission today that it has entered into a credit agreement for a principal amount of $300 million.

The revolving credit facility includes $10 million sublimits for swingline loans and letters of credit. Myriad borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.